Arizona resident brings national recognition, vast political experience and international financial savvy to non-profit engine of biomedical researchContinue reading
Author Archive: AZBio
Ventana launches fully automated Gram Stain on the BenchMark Special Stains platform
TUCSON, Ariz., Oct. 22, 2013 — Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the global launch of the VENTANA Gram Staining Kit(1) . Automated for use on the VENTANA BenchMark Special Stains instrument, the Gram Staining Kit aids pathologists in the most basic classification of bacteria into Gram-positive and Gram-negative bacteria in fixed tissue samples. Gram stain classification is clinically useful as it provides an initial indication of the nature of a patient’s infection.
The Gram stain is part of a family of histochemical special stains that many laboratories around the world still run manually today. In automating the stain, Ventana gives its customers an efficient and automated method to perform this technically challenging assay, enabling them to achieve increased productivity, consistency, and testing quality.
“Tissue diagnostics play a critical role in enabling accurate diagnosis and treatment decisions for cancer patients. Ventana is dedicated to providing laboratories, pathologists and their patients with novel assays, and we are empowering our customers to achieve greater efficiencies by automating common, yet labor-intensive tests like the Gram stain,” says Mara G. Aspinall, President, Ventana Medical Systems, Inc.
The Gram Staining kit is the newest addition to the Ventana product offerings on the highly successful, fully automated BenchMark Special Stains platform launched in mid-2012. The kit offers two counterstain options and testing protocol flexibility to meet pathologists’ individual preferences.
“The new Gram Staining Kit will provide our customers visual consistency and clarity rarely achieved with manual Gram staining protocols. Our commitment to quality and advancing diagnostic consistency through world-class automation shines with this new product,” says Adrian Ralph, Vice President, Primary Staining, Ventana Medical Systems, Inc.
Learn more about Special Stains, and watch the BenchMark Special Stains Time lapse video here
(1) The VENTANA Gram Stain Kit is being launched as a US Class I exempt/ CE-IVD product.
About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. (“VMSI”) (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company’s intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of “companion diagnostics” to identify the patients most likely to respond favorably to specific therapies. VENTANA, the VENTANA logo, and BenchMark are trademarks of Roche.
Visit www.ventana.com to learn more.
VMSI Media Relations Jacqueline Bucher Senior Director, Corporate Communications Phone: 520-877-7288 e-mail: Jacquie BucherSOURCE Ventana Medical Systems, Inc.
Tucson Chemistry Teacher Recognized for Advancing Diversity in the Chemical Sciences.
The American Chemical Society (ACS) has selected AZBio member Wilma Amaro, a chemistry teacher at Pueblo Magnet High School, as the Western Region recipient of the Stanley C. Israel Regional Award for Advancing Diversity in the Chemical Sciences.Continue reading
Washington Update: Summary of Legislation to Reopen the Government and Raise the Debt Ceiling
The following update is provided by AZBio as a member of the the Council of State Bioscience Associations Continue reading
UA Medical Student Earns Prestigious Physicians of Tomorrow Award
By Rebecca Ruiz-McGill, Arizona Health Sciences Center | October 16, 2013Continue reading
Help AZ develop a 21st Century Workforce
To address the current and future needs to develop a 21st Century Workforce, Arizona State University is teaming with the Maricopa Community Colleges and other 2-year schools in Arizona to establish educational programs that would supply the state’s industry with technicians or engineering assistants having specific high technology skills and knowledge.
As an industry, out inputs towards the design of these programs are important, so we are surveying technology companies to learn more about skill sets that your firm will require in technicians or engineering assistants (both now and in the future). In this survey, the skill sets being addressed pertain to micro- or nano-scale technologies used in manufacturing as well as research and development.
Survey link: http://surveys.questionpro.com/a/t/ABkVkZP44U
The survey should take less than 5 minutes to complete, and is designed for technical supervisory or management personnel. Your participation is very much appreciated. If you feel a colleague within your company is the more appropriate person to respond to this survey, please kindly forward this message. It is also possible that some companies will receive more than one request due to different points of contact in the various databases we used to compile our mailing list. We apologize for the duplication if that occurs.
Information obtained from each company will be held in the strictest confidence, and survey results will only be described in the aggregate. If you have any questions, please contact:
Dr. Mangala Joshua | Dr. Ray Tsui | |
Mesa Community College | Arizona State University | |
480-461-7053 | 480-206-4736 |
Convoy Therapeutics and Hugel Enter Co-Development Partnership
Convoy Therapeutics, a late pre-approval stage biotechnology company using its proprietary transdermal molecule delivery platform to enhance penetration of large molecules, and retention of small molecules into skin and cells announced today they have entered into a multi-million dollar co-development partnership for exclusive South Korean market rights to Convoy’s Khalay HATM featuring HylaRegenesisTM technology.Continue reading
Pancreatic cancer patient survival is ‘significantly higher’ with nab-paclitaxel, in study led by TGen and Scottsdale Healthcare
NEJM today publishes findings of international trial resulting in recent FDA approval of Abraxane (nab-paclitaxel) for patients with advanced pancreatic cancer.Continue reading
Washington Update: Get the Inside Scoop on Doings in DC
As a member of the Council of State Bioindustry Associations, AZBio is please to share this update with our AZBio Membership.Continue reading